Recipharm and ViroPharma have signed a commercial contract for the manufacture and supply of DuoCort’s Plenadren. ViroPharma will complete commercial scale-up manufacture of Plenadren, a hydrocortisone, modified release tablet for the treatment of adrenal insufficiency in adults. ViroPharma is also investing in new equipment at Recipharm’s manufacturing site to support large-scale commercial manufacture of the product.
 
The agreement follows Recipharm’s completion of initial scale-up under a contract with DuoCort Pharma AB, which was recently acquired by ViroPharma following Plenadren’s EMA Orphan Drug Designation.
 
Helene Fehrm, general manager of Recipharm Stockholm, said, “We are really pleased ViroPharma has chosen to work with Recipharm for commercial scale up following the highly successful relationship we had with DuoCort. We look forward to building a long-term relationship with ViroPharma for its production.”